| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | STRYKAGEN CORP | 1664 N VIRGINIA ST | RENO | NV | 89557-0001 | WASHOE | USA | R44OD030543 | Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | 000 | 4 | NIH | 11/15/2023 | $0 |
| | 2024 | 2023 | STRYKAGEN CORP | 1664 N VIRGINIA ST | RENO | NV | 89557-0001 | WASHOE | USA | R44OD030543 | Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | 000 | 4 | NIH | 11/15/2023 | $0 |
| | 2024 | 2021 | STRYKAGEN CORP | 1664 N VIRGINIA ST | RENO | NV | 89557-0001 | WASHOE | USA | R42OD030543 | Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | 000 | 3 | NIH | 4/9/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $958,973 ) |
| | 2023 | 2023 | STRYKAGEN CORP | 1664 N VIRGINIA ST | RENO | NV | 89557-0001 | WASHOE | USA | R44OD030543 | Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | 000 | 4 | NIH | 9/15/2023 | $677,438 |
| | 2023 | 2023 | STRYKAGEN CORP | 1664 N VIRGINIA ST | RENO | NV | 89557-0001 | WASHOE | USA | R44OD030543 | Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | 000 | 4 | NIH | 9/15/2023 | $281,535 |
|
| Issue Date FY: 2021 ( Subtotal = $752,426 ) |
| | 2021 | 2021 | STRYKAGEN CORP. | 1664 N VIRGINIA ST ROSS HALL 106 MS 321 | RENO | NV | 89557-0001 | WASHOE | USA | R42OD030543 | Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | 000 | 3 | NIH | 8/16/2021 | $752,426 |
| | 2021 | 2018 | STRYKAGEN CORP. | 1664 N VIRGINIA ST ROSS HALL 106 MS 321 | RENO | NV | 89557-0001 | WASHOE | USA | R41AR073696 | Galectin-1 Protein Therapy for Congenital Muscular Dystrophy | 000 | 1 | NIH | 12/4/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $747,570 ) |
| | 2020 | 2020 | STRYKAGEN CORP. | 1664 N VIRGINIA ST ROSS HALL 106 MS 321 | RENO | NV | 89557-0001 | WASHOE | USA | R42OD030543 | Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | 000 | 2 | NIH | 8/25/2020 | $747,570 |
|
| Issue Date FY: 2018 ( Subtotal = $225,000 ) |
| | 2018 | 2018 | STRYKAGEN CORP. | 1664 N VIRGINIA ST ROSS HALL 106 MS 321 | RENO | NV | 89557-0001 | WASHOE | USA | R41AR073696 | Galectin-1 Protein Therapy for Congenital Muscular Dystrophy | 000 | 1 | NIH | 6/22/2018 | $225,000 |
|
| Issue Date FY: 2017 ( Subtotal = $0 ) |
| | 2017 | 2015 | STRYKAGEN CORP. | 1664 N VIRGINIA ST ROSS HALL 106 MS 321 | RENO | NV | 89557-0001 | WASHOE | USA | R41AR067014 | Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy | 000 | 1 | NIH | 1/31/2017 | $0 |
| | 2017 | 2015 | STRYKAGEN CORP. | 1664 N VIRGINIA ST ROSS HALL 106 MS 321 | RENO | NV | 89557-0001 | WASHOE | USA | R41AR067019 | Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | 000 | 1 | NIH | 8/3/2017 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $230,142 ) |
| | 2015 | 2015 | STRYKAGEN CORP. | 1664 N VIRGINIA ST ROSS HALL 106 MS | RENO | NV | 89557 | WASHOE | USA | R41AR067019 | Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | 000 | 1 | NIH | 3/18/2015 | $224,999 |
| | 2015 | 2015 | STRYKAGEN CORP. | 1664 N VIRGINIA ST ROSS HALL 106 MS | RENO | NV | 89557 | WASHOE | USA | R41AR067014 | Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy | 000 | 1 | NIH | 7/7/2015 | $5,143 |
|
| Issue Date FY: 2014 ( Subtotal = $219,857 ) |
| | 2014 | 2014 | STRYKAGEN CORP. | 1664 N VIRGINIA ST ROSS HALL 106 MS | RENO | NV | 89557 | WASHOE | USA | R41AR067014 | Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy | 000 | 1 | NIH | 8/28/2014 | $219,857 |
|
|
